2,6-PYRIDINEDIAMINE, N6-[2-[[4-(2,4-DICHLOROPHENYL)-5-(1H-IMIDAZOL-1-YL)-2-PYRIMIDINYL]AMINO]ETHYL]-3-NITRO- Property

Density 

1.62

storage temp. 

-20°C

solubility 

insoluble in H2O; insoluble in EtOH; ≥8.1 mg/mL in DMSO with gentle warming

form 

powder

color 

white to brown

Safety

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H301Toxic if swalloed

Precautionary statements

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P262Do not get in eyes, on skin, or on clothing.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P271Use only outdoors or in a well-ventilated area.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P284Wear respiratory protection.

P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P320Specific treatment is urgent (see … on this label).

P330Rinse mouth.

P403+P233Store in a well-ventilated place. Keep container tightly closed.

P405Store locked up.

P501Dispose of contents/container to..…

2,6-PYRIDINEDIAMINE, N6-[2-[[4-(2,4-DICHLOROPHENYL)-5-(1H-IMIDAZOL-1-YL)-2-PYRIMIDINYL]AMINO]ETHYL]-3-NITRO- Chemical Properties,Usage,Production

Uses

CHIR 98014 has been used for the generation of small molecules neural progenitor cells and differentiation towards motor neurons. It has also been used as a Wnt/β-catenin pharmacological agonist in the cell-conditioned medium to perform chromatin immunoprecipitation (ChIP) studies in HT22 neurons.

Definition

ChEBI: CHIR-98014 is a member of the class of aminopyrimidines that is pyrimidine substituted by {2-[(6-amino-5-nitropyridin-2-yl)amino]ethyl}amino, 2,4-dichlorophenyl, and 1H-imidazol-1-yl groups at positions 2, 4 and 5, respectively. It is a potent ATP-competitive inhibitor of GSK3alpha and GSK3beta (IC50 values of 0.65 and 0.58 nM, respectively). It has a role as an EC 2.7.11.26 (tau-protein kinase) inhibitor, an apoptosis inducer, an antineoplastic agent, a hypoglycemic agent, a Wnt signalling activator and a tau aggregation inhibitor. It is a secondary amino compound, a dichlorobenzene, a member of imidazoles, a diaminopyridine, an aminopyrimidine and a C-nitro compound.

Biological Activity

chir-98014 is a potent inhibitor of gsk-3α and gsk-3β with ic50 values of 0.65 nm and 0.58 nm, respectively [1]gsk-3 (glycogen synthase kinase 3) is a serine/threonine protein kinase and plays a pivotal role in a number of central intracellular signaling pathways, including cellular proliferation, migration, inflammation and immune responses, glucose regulation, and apoptosis. recently, it has been reported that gsk-3 abnormally expressed in a variety of diseases, including type ii diabetes, alzheimer's disease, inflammation, cancer, and bipolar disorder [2, 3].chir-98014 is a potent gsk-3α and gsk-3β inhibitor. when tested with insulin receptor-expressing cho-ir cells or primary rat hepatocytes, chir-98014 stimulated the gs activity ratio as high as two- to three fold compared with basal in a dose dependent manner. similarly, in isolated type 1 skeletal muscle from insulin-sensitive lean zucker and from insulin-resistant zdf rats, administration of chir-98014 activated gs activity ratio [1]. in mouse es-d3 cells, chir-98014 treatment (48 and 72 hours later) resulted in a significant activation of the wnt/beta-catenin pathway via inhibiting gsk-3 [4].in markedly diabetic and insulin-resistant db/db mice model, oral administration of chir-98014 (30mg/kg) significantly reduced fasting hyperglycemia within 4 hours and improved glucose disposal during an ipgtt [1].

Biochem/physiol Actions

CHIR 98014 is a glycogen synthase kinase-3 (GSK-3) inhibitor with IC50 values of 0.65 nM and 0.58 nM for GSK3α and GSK3β, respectively. CHIR98014 is 500-fold to >10,000-fold selectivity for GSK-3 versus 20 other protein kinases tested, including closest homologs Cdc2 and ERK2.

target

GSK-3β

storage

Store at -20°C

References

[1]. ring, d.b., et al., selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. diabetes, 2003. 52(3): p. 588-95.
[2]. pan wa, et al. the rna recognition motif of nifk is required for rrna maturation during cell cycle progression. rna biol. 2015. 12(3):255-67.
[3]. mccubrey ja, et al. gsk-3 as potential target for therapeutic intervention in cancer. oncotarget. 2014. 5(10):2881-911.
[4]. naujok o, et al. cytotoxicity and activation of the wnt/beta-catenin pathway in mouse embryonic stem cells treated with four gsk3 inhibitors. bmc res notes. 2014. 7(1):273-281.